

**SPECIAL FEATURES****Highlights of This Issue 987****CCR Translations****989 Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer**Rodrigo Dienstmann  
*See related article, p. 1062***991 Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide**Ephraim Joseph Fuchs  
*See related article, p. 1019***Statistics in CCR****994 Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design**

Shigeyuki Matsui and John Crowley

**Review****1002 Immunotherapy of Lymphoma and Myeloma: Facts and Hopes**

Matthew J. Pianko, Alison J. Moskowitz, and Alexander M. Lesokhin

**CANCER THERAPY: CLINICAL****1011 Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies**

Issa F. Khouri, Irina Fernandez Curbelo, Francesco Turturro, Elias J. Jabbour, Denái R. Milton, Roland L. Bassett, Jr Luis M. Vence, James P. Allison, Alison M. Gulbis, and Padmanee Sharma

**1019 NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome**Elizabeth A. Griffiths, Pragya Srivastava, Junko Matsuzaki, Zachary Brumberger, Eunice S. Wang, Justin Kocent, Austin Miller, Gregory W. Roloff, Hong Yuen Wong, Benjamin E. Paluch, Linda G. Lutgen-Dunckley, Brandon L. Martens, Kunle Odunsi, Adam R. Karpf, Christopher S. Hourigan, and Michael J. Nemeth  
*See related commentary, p. 991***1030 Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study**

Edwin P. Hui, Brigitte B. Y. Ma, Herbert H. F. Loong, Frankie Mo, Leung Li, Ann D. King, Ki Wang, Anil T. Ahuja, Charles M. L. Chan, Connie W. C. Hui, Chi H. Wong, and Anthony T. C. Chan

**1038 The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)**

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, and David J. Kwiatkowski, for the LCMC2 investigators

**PERSONALIZED MEDICINE AND IMAGING****1048 CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma**

Hsin-Yu Fang, Natasha Stephens Münch, Margret Schottelius, Jonas Ingermann, Haibo Liu, Michael Schauer, Stefan Stangl, Gabriele Multhoff, Katja Steiger, Carlos Germgroß, Moritz Jesinghaus, Wilko Weichert, Anja A. Kühn, Antonia R. Sepulveda, Hans-Jürgen Wester, Timothy C. Wang, and Michael Quante

**1062 Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes**Jonathan M. Loree, Allan A.L. Pereira, Michael Lam, Alexandra N. Willauer, Kanwal Raghav, Arvind Dasari, Van. K. Morris, Shailesh Advani, David G. Menter, Cathy Eng, Kenna Shaw, Russell Broadbudd, Mark J. Routbort, Yusha Liu, Jeffrey S. Morris, Rajyalakshmi Luthra, Funda Meric-Bernstam, Michael J. Overman, Dipen Maru, and Scott Kopetz  
*See related commentary, p. 989*

# Table of Contents

- 1073 Residual Convolutional Neural Network for the Determination of *IDH* Status in Low- and High-Grade Gliomas from MR Imaging**  
Ken Chang, Harrison X. Bai, Hao Zhou, Chang Su, Wenya Linda Bi, Ena Agbodza, Vasileios K. Kavouridis, Joeky T. Senders, Alessandro Boaro, Andrew Beers, Biqi Zhang, Alexandra Capellini, Weihua Liao, Qin Shen, Xuejun Li, Bo Xiao, Jane Cryan, Shakti Ramkissoon, Lori Ramkissoon, Keith Ligon, Patrick Y. Wen, Ranjit S. Bindra, John Woo, Omar Arnaout, Elizabeth R. Gerstner, Paul J. Zhang, Bruce R. Rosen, Li Yang, Raymond Y. Huang, and Jayashree Kalpathy-Cramer
- 1082 Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study**  
Filippo Pietrantonio, Giovanni Fucà, Federica Morano, Annunziata Gloghini, Simona Corso, Giuseppe Aprile, Federica Perrone, Ferdinando De Vita, Elena Tamborini, Gianluca Tomasello, Ambra Vittoria Gualeni, Elena Ongaro, Adele Busico, Elisa Giommoni, Chiara Costanza Volpi, Maria Maddalena Laterza, Salvatore Corallo, Michele Prisciandaro, Maria Antista, Alessandro Pellegrinelli, Lorenzo Castagnoli, Serenella M. Pupa, Giancarlo Pruneri, Filippo de Braud, Silvia Giordano, Chiara Cremolini, and Maria Di Bartolomeo
- CANCER THERAPY: PRECLINICAL**
- 1090 Acetylsalicylic Acid Governs the Effect of Sorafenib in *RAS*-Mutant Cancers**  
Heinz Hammerlindl, Dinoop Ravindran Menon, Sabrina Hammerlindl, Abdullah Al Emran, Joachim Torrano, Katrin Sproesser, Divya Thakkar, Min Xiao, Victoria G. Atkinson, Brian Gabrielli, Nikolas K. Haass, Meenhard Herlyn, Clemens Krepler, and Helmut Schaidler
- 1103 Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K $\delta$  in Mature B-cell Malignancies**  
Jeffrey D. Cooney, An-Ping Lin, Daifeng Jiang, Long Wang, Avvaru N. Suhasini, Jamie Myers, ZhiJun Qiu, Albert Wölfler, Heinz Sill, and Ricardo C.T. Aguiar
- 1114 Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies *In Vivo***  
Hong Qin, Guowei Wei, Ippei Sakamaki, Zhenyuan Dong, Wesley A. Cheng, D. Lynne Smith, Feng Wen, Han Sun, Kunhwa Kim, Soungchul Cha, Laura Bover, Sattva S. Neelapu, and Larry W. Kwak
- 1124 Novel Targeting of Transcription and Metabolism in Glioblastoma**  
Yu-Ting Su, Robert Chen, Herui Wang, Hua Song, Qi Zhang, Li-Yuan Chen, Hallie Lappin, Gabriel Vasconcelos, Adrian Lita, Dragan Maric, Aiguo Li, Orieta Celiku, Wei Zhang, Kristan Meetze, Thomas Estok, Mioara Larion, Mones Abu-Asab, Zhengping Zhuang, Chunzhang Yang, Mark R. Gilbert, and Jing Wu
- 1138 Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway**  
Todd Bartkowiak, Ashvin R. Jaiswal, Casey R. Ager, Renee Chin, Chao-Hsien Chen, Pratha Budhani, Midan Ai, Matthew J. Reilley, Manu M. Sebastian, David S. Hong, and Michael A. Curran
- 1152 Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer**  
Daniel Dávila-González, Dong Soon Choi, Roberto R. Rosato, Sergio M. Granados-Principal, John G. Kuhn, Wen-Feng Li, Wei Qian, Wen Chen, Anthony J. Kozielski, Helen Wong, Bhuvanesh Dave, and Jenny C. Chang
- 1163 HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue**  
Guopei Zheng, Zhijie Zhang, Hao Liu, Yan Xiong, Liyun Luo, Xiaoting Jia, Cong Peng, Qiong Zhang, Nan Li, Yixue Gu, Mingying Lu, Ying Song, Hao Pan, Jinbao Liu, Wanqing Liu, and Zhimin He
- 1176 Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer**  
Chun-Han Chen, Chun A. Changou, Tsung-Han Hsieh, Yu-Ching Lee, Cheng-Ying Chu, Kai-Cheng Hsu, Hao-Ching Wang, Yu-Chen Lin, Yan-Ni Lo, Yun-Ru Liu, Jing-Ping Liou, and Yun Yen
- 1190 Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice**  
Elizabeth K. Duperret, Aspen Trautz, Dylan Ammons, Alfredo Perales-Puchalt, Megan C. Wise, Jian Yan, Charles Reed, and David B. Weiner

# Table of Contents

## BIOLOGY OF HUMAN TUMORS

**1202** *NAMPT* Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP

Antonio Lucena-Cacace, Daniel Otero-Albiol, Manuel P. Jiménez-García, Sandra Muñoz-Galvan, and Amancio Carnero

**1216** *t-Darpp* Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells

Gal Lenz, Angelica Hamilton, Shuhui Geng, Teresa Hong, Markus Kalkum, Jamil Momand, Susan E. Kane, and Janice M. Huss

**1227** Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling



Mingxiang Ye, Yong Zhang, Hongjun Gao, Yan Xu, Pengyu Jing, Jianxiong Wu, Xinxin Zhang, Jie Xiong, Chenfang Dong, Libo Yao, Jian Zhang, and Jian Zhang




AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows high-grade dysplasia lesions along the squamocolumnar junction (SCJ) or cardia in a mouse model of Barrett Esophagus and adenocarcinoma with immune and stromal cell infiltration. PET tracer ex vivo autoradiography showed that CXCR4 is a specific marker for such immune and epithelial cells that accumulate gradually while dysplasia progresses, which are mediators of disease progression and therefore emerge as a potential biomarker in humans. For details, see the article by Fang and colleagues on page 1048 of this issue.



# Clinical Cancer Research

**24 (5)**

*Clin Cancer Res* 2018;24:987-1239.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/24/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/24/5>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.